AF / 1624 PTO/SB/21 (08-00)

TRANSM	IITT A I		Application Num	ber	10/026,949		
		Filing Date		December 27, 2001			
		First Named Inve	ntor	Yusuf K. HAMIED et al.			
to be used for all correspondence after initial filing)			Group Art Unit		1624		
			Examiner Name		Brenda Libby COLEMAN		
Total Number of Pages in This Submission			Attorney Docket N	lumber	33396-17720		
		ENCLO	OSURES (check all the	at apply)			
Fee Transmittal Form		Assignment Papers (for an Application)			After Allowance Communication Group		
Fee Attached		Drawing(s)			Appeal Communication to Boar Appeals and Interferences		
Amendment / Response		Licensing-related Papers			Appeal Communication to Grou (Appeal Notice, Brief, Reply Brief)		
After Final		Petition			Proprietary Information		
Affidavits/declaration(s)		Petition to Convert to a Provisional Application		Status Letter			
Extension of Time Request		Power of Attorney, Revocation Change of Correspondence Address		Other Enclosure(s) (please identify below):			
		Terminal Disclaimer					
Express Abandonment Request		Request for Refund					
☐ Information Disclosure Statement		CD, Number of CD(s)					
Certified Copy of Priority Document(s)		Remai	rks	,			
Response to Missing Pa Incomplete Application	rts/		<del></del>				
Response to Missing Parts under 37 CFR 1.52 or 1.53	1						
	SIGNAT	URE OF A	APPLICANT, ATTO	RNEY, O	R AGENT		
Firm <i>or</i> Individual name		, 1			26694 Patent trademark office		
Signature	46 x	Hold		Keith G. Ha	addaway, Ph.D., Reg. No. 46,180		
Date Octob	er 7, 2005						
		CEF	RTIFICATE OF MAI	ĻING			
I hereby certify that this corresp	ondence is being	g deposited v	vith the United States Po	stal Service	as first class mail in an envelope		





Docket No.: 33396-177202

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Yusuf K. HAMIED et al.

Confirmation No.: 7990

Application No.: 10/026,949

Art Unit: 1624

Filed: December 27, 2001

Examiner: Brenda Libby COLEMAN

For: PHARMACEUTICAL COMPOSITIONS

CONTAINING NEW POLYMORPHIC FORMS OF OLANZAPINE AND USES THEREOF

Customer No.

26694

Amendment and Reply Under 37 C.F.R. § 1.116

MAIL STOP: AF

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Please amend the above-identified application as follows.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are needed to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims), and any other fee deficiency are hereby authorized to be charged, any overpayments credited to, our Deposit Account No. 22-0261.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 11 of this paper.